The exercise period for Prostatype Genomic’s warrants of series 3 begins today
The exercise period for the warrants of series 3 (the "Warrants" or “TO3”) issued in connection with Prostatype Genomic AB ("Prostatype Genomics" or the "Company") rights issue of units announced on November 7, 2023 (the "Rights Issue") begins today and runs up to, and including, April 19, 2024. The exercise price is set at SEK 0.04 per share. Each Warrant entitles the holder to subscribe for one new share in Prostatype Genomics, and upon full exercise of the Warrants, the Company will receive approximately SEK 10.0 million before deductions for issuing costs.“From today you can exercise